

CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOLUME 1–46

acetylcholine receptors, 30, 41; 40, 3
 acetylcholine transporter, 28, 247
 acetyl CoA carboxylase (ACC) inhibitors, 45, 95
 acyl sulfonamide anti-proliferatives, 41, 251
 adenylate cyclase, 6, 227, 233; 12, 172; 19, 293; 29, 287
 adenosine, 33, 111
 adenosine, neuromodulator, 18, 1; 23, 39
 adenosine receptor ligands, 44, 265
 A3 adenosine receptors, 38, 121
 adjuvants, 9, 244
 ADME by computer, 36, 257
 ADME, computational models, 42, 449
 ADME properties, 34, 307
 adrenal steroidogenesis, 2, 263
 adrenergic receptor antagonists, 35, 221
 β -adrenergic blockers, 10, 51; 14, 81
 β -adrenergic receptor agonists, 33, 193
 β_2 -adrenoceptor agonists, long acting, 41, 237
 aerosol delivery, 37, 149
 affinity labeling, 9, 222
 β_3 -agonists, 30, 189
 AIDS, 23, 161, 253; 25, 149
 AKT kinase inhibitors, 40, 263
 alcohol consumption, drugs and deterrence, 4, 246
 aldose reductase, 19, 169
 alkaloids, 1, 311; 3, 358; 4, 322; 5, 323; 6, 274
 allergic eosinophilia, 34, 61
 allergy, 29, 73
 alopecia, 24, 187
 Alzheimer's Disease, 26, 229; 28, 49, 197, 247; 32, 11; 34, 21; 35, 31; 40, 35
 Alzheimer's Disease Research, 37, 31
 Alzheimer's Disease Therapies, 37, 197; 40, 35
 aminocyclitol antibiotics, 12, 110
 β -amyloid, 34, 21
 amyloid, 28, 49; 32, 11
 amyloidogenesis, 26, 229
 analgesics (analgetic), 1, 40; 2, 33; 3, 36; 4, 37; 5, 31; 6, 34; 7, 31; 8, 20; 9, 11; 10, 12; 11, 23; 12, 20; 13, 41; 14, 31; 15, 32; 16, 41; 17, 21; 18, 51; 19, 1; 20, 21; 21, 21; 23, 11; 25, 11; 30, 11; 33, 11
 androgen action, 21, 179; 29, 225
 androgen receptor modulators, 36, 169
 anesthetics, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39; 8, 29; 10, 30, 31, 41
 angiogenesis inhibitors, 27, 139; 32, 161
 angiotensin/renin modulators, 26, 63; 27, 59
 animal engineering, 29, 33
 animal healthcare, 36, 319
 animal models, anxiety, 15, 51
 animal models, memory and learning, 12, 30
 Annual Reports in Medicinal Chemistry, 25, 333

anorexigenic agents, 1, 51; 2, 44; 3, 47; 5, 40; 8, 42; 11, 200; 15, 172
 antagonists, calcium, 16, 257; 17, 71; 18, 79
 antagonists, GABA, 13, 31; 15, 41; 39, 11
 antagonists, narcotic, 7, 31; 8, 20; 9, 11; 10, 12; 11, 23
 antagonists, non-steroidal, 1, 213; 2, 208; 3, 207; 4, 199
 Antagonists, PGD2, 41, 221
 antagonists, steroidal, 1, 213; 2, 208; 3, 207; 4, 199
 antagonists of VLA-4, 37, 65
 anthracycline antibiotics, 14, 288
 antiaging drugs, 9, 214
 antiallergy agents, 1, 92; 2, 83; 3, 84; 7, 89; 9, 85; 10, 80; 11, 51; 12, 70; 13, 51; 14, 51; 15, 59; 17, 51; 18, 61; 19, 93; 20, 71; 21, 73; 22, 73; 23, 69; 24, 61; 25, 61; 26, 113; 27, 109
 antianginals, 1, 78; 2, 69; 3, 71; 5, 63; 7, 69; 8, 63; 9, 67; 12, 39; 17, 71
 anti-angiogenesis, 35, 123
 antianxiety agents, 1, 1; 2, 1; 3, 1; 4, 1; 5, 1; 6, 1; 7, 6; 8, 1; 9, 1; 10, 2; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22; 16, 31; 17, 11; 18, 11; 19, 11; 20, 1; 21, 11; 22, 11; 23, 19; 24, 11
 antiapoptotic proteins, 40, 245
 antiarrhythmic agents, 41, 169
 antiarrhythmics, 1, 85; 6, 80; 8, 63; 9, 67; 12, 39; 18, 99, 21, 95; 25, 79; 27, 89
 antibacterial resistance mechanisms, 28, 141
 antibacterials, 1, 118; 2, 112; 3, 105; 4, 108; 5, 87; 6, 108; 17, 107; 18, 29, 113; 23, 141; 30, 101; 31, 121; 33, 141; 34, 169; 34, 227; 36, 89; 40, 301
 antibacterial targets, 37, 95
 antibiotic transport, 24, 139
 antibiotics, 1, 109; 2, 102; 3, 93; 4, 88; 5, 75, 156; 6, 99; 7, 99, 217; 8, 104; 9, 95; 10, 109, 246; 11, 89; 11, 271; 12, 101, 110; 13, 103, 149; 14, 103; 15, 106; 17, 107; 18, 109; 21, 131; 23, 121; 24, 101; 25, 119; 37, 149; 42, 349
 antibiotic producing organisms, 27, 129
 antibodies, cancer therapy, 23, 151
 antibodies, drug carriers and toxicity reversal, 15, 233
 antibodies, monoclonal, 16, 243
 antibody drug conjugates, 38, 229
 anticancer agents, mechanical-based, 25, 129
 anticancer drug resistance, 23, 265
 anticoagulants, 34, 81; 36, 79; 37, 85
 anticoagulant agents, 35, 83
 anticoagulant/antithrombotic agents, 40, 85
 anticonvulsants, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39, 8, 29; 10, 30; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22; 16, 31; 17, 11; 18, 11; 19, 11; 20, 11; 21, 11; 23, 19; 24, 11
 antidepressants, 1, 12; 2, 11; 3, 14; 4, 13; 5, 13; 6, 15; 7, 18; 8, 11; 11, 3; 12, 1; 13, 1; 14, 1; 15, 1; 16, 1; 17, 41; 18, 41; 20, 31; 22, 21; 24, 21; 26, 23; 29, 1; 34, 1
 antidepressant drugs, new, 41, 23
 antidiabetics, 1, 164; 2, 176; 3, 156; 4, 164; 6, 192; 27, 219
 antiepileptics, 33, 61
 antifungal agents, 32, 151; 33, 173, 35, 157
 antifungal drug discovery, 38, 163; 41, 299
 antifungals, 2, 157; 3, 145; 4, 138; 5, 129; 6, 129; 7, 109; 8, 116; 9, 107; 10, 120; 11, 101; 13, 113; 15, 139; 17, 139; 19, 127; 22, 159; 24, 111; 25, 141; 27, 149
 antiglaucoma agents, 20, 83
 anti-HCV therapeutics, 34, 129; 39, 175
 antihyperlipidemics, 15, 162; 18, 161; 24, 147

- antihypertensives, 1, 59; 2, 48; 3, 53; 4, 47; 5, 49; 6, 52; 7, 59; 8, 52; 9, 57; 11, 61; 12, 60; 13, 71; 14, 61; 15, 79; 16, 73; 17, 61; 18, 69; 19, 61; 21, 63; 22, 63; 23, 59; 24, 51
- antiinfective agents, 28, 119
- antiinflammatory agents, 28, 109; 29, 103
- anti-inflammatories, 37, 217
- anti-inflammatories, non-steroidal, 1, 224; 2, 217; 3, 215; 4, 207; 5, 225; 6, 182; 7, 208; 8, 214; 9, 193; 10, 172; 13, 167; 16, 189; 23, 181
- anti-ischemic agents, 17, 71
- antimalarial inhibitors, 34, 159
- antimetabolite cancer chemotherapies, 39, 125
- antimetabolite concept, drug design, 11, 223
- antimicrobial drugs—clinical problems and opportunities, 21, 119
- antimicrobial potentiation, 33, 121
- antimicrobial peptides, 27, 159
- antimitotic agents, 34, 139
- antimycobacterial agents, 31, 161
- antineoplastics, 2, 166; 3, 150; 4, 154; 5, 144; 7, 129; 8, 128; 9, 139; 10, 131; 11, 110; 12, 120; 13, 120; 14, 132; 15, 130; 16, 137; 17, 163; 18, 129; 19, 137; 20, 163; 22, 137; 24, 121; 28, 167
- anti-obesity agents, centrally acting, 41, 77
- antiparasitics, 1, 136, 150; 2, 131, 147; 3, 126, 140; 4, 126; 5, 116; 7, 145; 8, 141; 9, 115; 10, 154; 121; 12, 140; 13, 130; 14, 122; 15, 120; 16, 125; 17, 129; 19, 147; 26, 161
- antiparkinsonism drugs, 6, 42; 9, 19
- antiplatelet therapies, 35, 103
- antipsychotics, 1, 1; 2, 1; 3, 1; 4, 1; 5, 1; 6, 1; 7, 6; 8, 1; 9, 1; 10, 2; 11, 3; 12, 1; 13, 11; 14, 12; 15, 12; 16, 11; 18, 21; 19, 21; 21, 1; 22, 1; 23, 1; 24, 1; 25, 1; 26, 53; 27, 49; 28, 39; 33, 1
- antiradiation agents, 1, 324; 2, 330; 3, 327; 5, 346
- anti-resorptive and anabolic bone agents, 39, 53
- anti-retroviral chemotherapy, 25, 149
- antiretroviral drug therapy, 32, 131
- antiretroviral therapies, 35, 177; 36, 129
- antirheumatic drugs, 18, 171
- anti-SARS coronavirus chemistry, 41, 183
- antisense oligonucleotides, 23, 295; 33, 313
- antisense technology, 29, 297
- antithrombotics, 7, 78; 8, 73; 9, 75; 10, 99; 12, 80; 14, 71; 17, 79; 27, 99; 32, 71
- antithrombotic agents, 29, 103
- antitumor agents, 24, 121
- antitussive therapy, 36, 31
- antiviral agents, 1, 129; 2, 122; 3, 116; 4, 117; 5, 101; 6, 118; 7, 119; 8, 150; 9, 128; 10, 161; 11, 128; 13, 139; 15, 149; 16, 149; 18, 139; 19, 117; 22, 147; 23, 161; 24, 129; 26, 133; 28, 131; 29, 145; 30, 139; 32, 141; 33, 163; 37, 133; 39, 241
- antitussive therapy, 35, 53
- anxiolytics, 26, 1
- apoptosis, 31, 249
- aporphine chemistry, 4, 331
- arachidonate lipooxygenase, 16, 213
- arachidonic acid cascade, 12, 182; 14, 178
- arachidonic acid metabolites, 17, 203; 23, 181; 24, 71
- artemisinin derivatives, 44, 359
- arthritis, 13, 167; 16, 189; 17, 175; 18, 171; 21, 201; 23, 171, 181; 33, 203
- arthritis, immunotherapy, 23, 171
- aryl hydrocarbon receptor activation, 46, 319

aspartyl proteases, 36, 247
asthma, 29, 73; 32, 91
asymmetric synthesis, 13, 282
atherosclerosis, 1, 178; 2, 187; 3, 172; 4, 178; 5, 180; 6, 150; 7, 169; 8, 183; 15, 162; 18, 161; 21, 189; 24, 147; 25, 169; 28, 217; 32, 101; 34, 101; 36, 57; 40, 71
atherosclerosis HDL raising therapies, 40, 71
atherothrombogenesis, 31, 101
atrial natriuretic factor, 21, 273; 23, 101
attention deficit hyperactivity disorder, 37, 11; 39, 1
autoimmune diseases, 34, 257; 37, 217
autoreceptors, 19, 51
BACE inhibitors, 40, 35
bacterial adhesins, 26, 239
bacterial genomics, 32, 121
bacterial resistance, 13, 239; 17, 119; 32, 111
bacterial toxins, 12, 211
bacterial virulence, 30, 111
basophil degranulation, biochemistry, 18, 247
B-cell receptor pathway in inflammatory disease, 45, 175
Bcl2 family, 31, 249; 33, 253
behavior, serotonin, 7, 47
benzodiazepine receptors, 16, 21
bile acid receptor modulators, 46, 69
biofilm-associated infections, 39, 155
bioinformatics, 36, 201
bioisosteric groups, 38, 333
bioisosterism, 21, 283
biological factors, 10, 39; 11, 42
biological membranes, 11, 222
biological systems, 37, 279
biopharmaceutics, 1, 331; 2, 340; 3, 337; 4, 302; 5, 313; 6, 264; 7, 259; 8, 332
biosensor, 30, 275
biosimulation, 37, 279
biosynthesis, antibiotics, 12, 130
biotechnology, drug discovery, 25, 289
biowarfare pathogens, 39, 165
blood-brain barrier, 20, 305; 40, 403
blood enzymes, 1, 233
bone, metabolic disease, 12, 223; 15, 228; 17, 261; 22, 169
bone metabolism, 26, 201
bradykinin-1 receptor antagonists, 38, 111
bradykinin B2 antagonists, 39, 89
brain, decade of, 27, 1
C5a antagonists, 39, 109
C5a receptor antagonists, 46, 171
calcium antagonists/modulators, 16, 257; 17, 71; 18, 79; 21, 85
calcium channels, 30, 51
calmodulin antagonists, SAR, 18, 203
cancer, 27, 169; 31, 241; 34, 121; 35, 123; 35, 167
cancer chemosensitization, 37, 115
cancer chemotherapy, 29, 165; 37, 125
cancer cytotoxics, 33, 151

cancer, drug resistance, 23, 265
cancer therapy, 2, 166; 3, 150; 4, 154; 5, 144; 7, 129; 8, 128; 9, 139, 151; 10, 131; 11, 110; 12, 120; 13, 120; 14, 132; 15, 130; 16, 137; 17, 163; 18, 129; 21, 257; 23, 151; 37, 225; 39, 125
cannabinoid receptors, 9, 253; 34, 199
cannabinoid, receptors, CB1, 40, 103
cannabinoid (CB2) selective agonists, 44, 227
capsid assembly pathway modulators, 46, 283
carbohydrates, 27, 301
carboxylic acid, metalated, 12, 278
carcinogenicity, chemicals, 12, 234
cardiotonic agents, 13, 92; 16, 93; 19, 71
cardiovascular, 10, 61
case history: Chantix (varenicline tartrate), 44, 71
case history: Ixabepilone (ixempra®), 44, 301
case history -JANUVIA®, 42, 95
case history -Tegaserod, 42, 195
case history: Tekturna® /rasilez® (aliskiren), 44, 105
caspases, 33, 273
catalysis, intramolecular, 7, 279
catalytic antibodies, 25, 299; 30, 255
Cathepsin K, 39, 63
CCR1 antagonists, 39, 117
CCR2 antagonists, 42, 211
CCR3 antagonists, 38, 131
cell adhesion, 29, 215
cell adhesion molecules, 25, 235
cell based mechanism screens, 28, 161
cell cycle, 31, 241; 34, 247
cell cycle kinases, 36, 139
cell invasion, 14, 229
cell metabolism, 1, 267
cell metabolism, cyclic AMP, 2, 286
cellular pathways, 37, 187
cellular responses, inflammatory, 12, 152
CFTR modulators for the treatment of cystic fibrosis, 45, 157
chemical tools, 40, 339
chemical proteomic technologies for drug target identification, 45, 345
cheminformatics, 38, 285
chemogenomics, 38, 285
chemoinformatics, 33, 375
chemokines, 30, 209; 35, 191; 39, 117
chemotaxis, 15, 224; 17, 139, 253; 24, 233
chemotherapy of HIV, 38, 173
cholecystokinin, 18, 31
cholecystokinin agonists, 26, 191
cholecystokinin antagonists, 26, 191
cholesteryl ester transfer protein, 35, 251
chronic obstructive pulmonary disease, 37, 209
chronopharmacology, 11, 251
circadian processes, 27, 11
circadian rhythm modulation via CK1 inhibition, 46, 33
Clostridium difficile treatments, 43, 269

CNS medicines, 37, 21
CNS PET imaging agents, 40, 49
coagulation, 26, 93; 33, 81
co-crystals in drug discovery, 43, 373
cognition enhancers, 25, 21
cognitive disorders, 19, 31; 21, 31; 23, 29; 31, 11
collagenase, biochemistry, 25, 177
collagenases, 19, 231
colony stimulating factor, 21, 263
combinatorial chemistry, 34, 267; 34, 287
combinatorial libraries, 31, 309; 31, 319
combinatorial mixtures, 32, 261
complement cascade, 27, 199; 39, 109
complement inhibitors, 15, 193
complement system, 7, 228
compound collection enhancement and high throughput screening, 45, 409
conformation, nucleoside, biological activity, 5, 272
conformation, peptide, biological activity, 13, 227
conformational analysis, peptides, 23, 285
congestive heart failure, 22, 85; 35, 63
contrast media, NMR imaging, 24, 265
corticotropin-releasing factor, 25, 217; 30, 21; 34, 11; 43, 3
corticotropin-releasing hormone, 32, 41
cotransmitters, 20, 51
CRTh2 antagonists, 46, 119
CXCR3 antagonists, 40, 215
cyclic AMP, 2, 286; 6, 215; 8, 224; 11, 291
cyclic GMP, 11, 291
cyclic nucleotides, 9, 203; 10, 192; 15, 182
cyclin-dependent kinases, 32, 171
cyclooxygenase, 30, 179
cyclooxygenase-2 inhibitors, 32, 211; 39, 99
cysteine proteases, 35, 309; 39, 63
cystic fibrosis, 27, 235; 36, 67
cytochrome P-450, 9, 290; 19, 201; 32, 295
cytochrome P-450 inhibition, 44, 535
cytokines, 27, 209; 31, 269; 34, 219
cytokine receptors, 26, 221
database searching, 3D, 28, 275
DDT-type insecticides, 9, 300
dermal wound healing, 24, 223
dermatology and dermatological agents, 12, 162; 18, 181; 22, 201; 24, 177
designer enzymes, 25, 299
deuterium in drug discovery and development, 46, 403
diabetes, 9, 182; 11, 170; 13, 159; 19, 169; 22, 213; 25, 205; 30, 159; 33, 213; 39, 31; 40, 167
diabetes targets, G-Protein coupled receptors, 42, 129
Diels-Alder reaction, intramolecular, 9, 270
dipeptidyl, peptidase 4, inhibitors, 40, 149
discovery indications, 40, 339
distance geometry, 26, 281
diuretic, 1, 67; 2, 59; 3, 62; 6, 88; 8, 83; 10, 71; 11, 71; 13, 61; 15, 100
DNA binding, sequence-specific, 27, 311; 22, 259

DNA vaccines, 34, 149
docking strategies, 28, 275
dopamine, 13, 11; 14, 12; 15, 12; 16, 11, 103; 18, 21; 20, 41; 22, 107
dopamine D3, 29, 43
dopamine D4, 29, 43
DPP-IV Inhibition, 36, 191
drug attrition associated with physicochemical properties, 45, 393
drug abuse, 43, 61
drug abuse, CNS agents, 9, 38
drug allergy, 3, 240
drug carriers, antibodies, 15, 233
drug carriers, liposomes, 14, 250
drug delivery systems, 15, 302; 18, 275; 20, 305
drug design, 34, 339
drug design, computational, 33, 397
drug design, knowledge and intelligence in, 41, 425
drug design, metabolic aspects, 23, 315
drug discovery, 17, 301; 34, ; 34, 307
drug discovery, bioactivation in, 41, 369
drug discovery for neglected tropical diseases, 45, 277
drug disposition, 15, 277
drug metabolism, 3, 227; 4, 259; 5, 246; 6, 205; 8, 234; 9, 290; 11, 190; 12, 201; 13, 196, 304; 14, 188, 16, 319; 17, 333; 23, 265, 315; 29, 307
drug receptors, 25, 281
drug repositioning, 46, 385
drug resistance, 23, 265
drug safety, 40, 387
dynamic modeling, 37, 279
dyslipidemia and insulin resistance enzyme targets, 42, 161
EDRF, 27, 69
elderly, drug action, 20, 295
electrospray mass spectrometry, 32, 269
electrosynthesis, 12, 309
enantioselectivity, drug metabolism, 13, 304
endorphins, 13, 41; 14, 31; 15, 32; 16, 41; 17, 21; 18, 51
endothelin, 31, 81; 32, 61
endothelin antagonism, 35, 73
endothelin antagonists, 29, 65, 30, 91
enzymatic monooxygenation reactions, 15, 207
enzyme induction, 38, 315
enzyme inhibitors, 7, 249; 9, 234; 13, 249
enzyme immunoassay, 18, 285
enzymes, anticancer drug resistance, 23, 265
enzymes, blood, 1, 233
enzymes, proteolytic inhibition, 13, 261
enzyme structure-function, 22, 293
enzymic synthesis, 19, 263; 23, 305
epitopes for antibodies, 27, 189
erectile dysfunction, 34, 71
Eribulin (HALAVENTM) case history, 46, 227
estrogen receptor, 31, 181
estrogen receptor modulators, SERMS, 42, 147

ethnobotany, 29, 325
excitatory amino acids, 22, 31; 24, 41; 26, 11; 29, 53
ex-vivo approaches, 35, 299
factor VIIa, 37, 85
factor Xa, 31, 51; 34, 81
factor Xa inhibitors, 35, 83
Fc receptor structure, 37, 217
fertility control, 10, 240; 14, 168; 21, 169
filarial nematodes, 35, 281
fluorine in the discovery of CNS agents, 45, 429
FMS kinase inhibitors, 44, 211
formulation in drug discovery, 43, 419
forskolin, 19, 293
fragment-based lead discovery, 42, 431
free radical pathology, 10, 257; 22, 253
fungal nail infections, 40, 323
fungal resistance, 35, 157
G-proteins, 23, 235
G-proteins coupled receptor modulators, 37, 1
GABA, antagonists, 13, 31; 15, 41
galanin receptors, 33, 41
gamete biology, fertility control, 10, 240
gastrointestinal agents, 1, 99; 2, 91; 4, 56; 6, 68; 8, 93; 10, 90; 12, 91; 16, 83; 17, 89; 18, 89; 20, 117; 23, 201, 38, 89
gastrointestinal prokinetic agents, 41, 211, 46, 135
gastrointestinal tracts of mammals, 43, 353
gender based medicine, 33, 355
gene expression, 32, 231
gene expression, inhibitors, 23, 295
gene knockouts in mice as source of new targets, 44, 475
gene targeting technology, 29, 265
gene therapy, 8, 245; 30, 219
genetically modified crops, 35, 357
gene transcription, regulation of, 27, 311
genomic data mining, 41, 319
genomics, 34, 227; 40, 349
ghrelin receptor modulators, 38, 81
glucagon, 34, 189
glucagon, mechanism, 18, 193
glucagon receptor antagonists, 43, 119
 β -D-glucans, 30, 129
glucocorticoid receptor modulators, 37, 167
glucocorticosteroids, 13, 179
Glucokinase Activators, 41, 141
glutamate, 31, 31
glycine transporter-1 inhibitors, 45, 19
glycoconjugate vaccines, 28, 257
glycogen synthase kinase-3 (GSK-3), 40, 135; 44, 3
glycolysis networks model, 43, 329
glycopeptide antibiotics, 31, 131
glycoprotein IIb/IIIa antagonists, 28, 79
glycosylation, non-enzymatic, 14, 261

gonadal steroid receptors, 31, 11
gonadotropin receptor ligands, 44, 171
gonadotropin releasing hormone, 30, 169; 39, 79
GPIIb/IIIa, 31, 91
Gpr119 agonists, 44, 149
GPR40 (FFAR1) modulators, 43, 75
G-Protein coupled receptor inverse agonists, 40, 373
G protein-coupled receptors, 35, 271
gram-negative pathogen antibiotics, 46, 245
growth factor receptor kinases, 36, 109
growth factors, 21, 159; 24, 223; 28, 89
growth hormone, 20, 185
growth hormone secretagogues, 28, 177; 32, 221
guanylyl cyclase, 27, 245
hallucinogens, 1, 12; 2, 11; 3, 14; 4, 13; 5, 23; 6, 24
HDL cholesterol, 35, 251
HDL modulating therapies, 42, 177
health and climate change, 38, 375
heart disease, ischemic, 15, 89; 17, 71
heart failure, 13, 92; 16, 93; 22, 85
hedgehog pathway inhibitors, 44, 323
HCV antiviral agents, 39, 175
HDAC inhibitors and LSD1 inhibitors, 45, 245
helicobacter pylori, 30, 151
hemoglobins, 34, 159
hemorheologic agents, 17, 99
hepatitis C viral inhibitors, 44, 397
hepatitis C virus inhibitors of non-enzymatic viral proteins, 46, 263
herbicides, 17, 311
heterocyclic chemistry, 14, 278
HIF prolyl hydroxylase, 45, 123
high throughput screening, 33, 293
histamine H3 receptor agents, 33, 31; 39, 45
histamine H3 receptor antagonists, 42, 49
histone deacetylase inhibitors, 39, 145
hit-to-lead process, 39, 231
HIV co-receptors, 33, 263
HIV-1 integrase strand transfer inhibitors, 45, 263
HIV prevention strategies, 40, 277
HIV protease inhibitors, 26, 141; 29, 123
HIV reverse transcriptase inhibitors, 29, 123
HIV therapeutics, 40, 291
HIV vaccine, 27, 255
HIV viral entry inhibitors, CCR5 and CXCR4, 42, 301
homeobox genes, 27, 227
hormones, glycoprotein, 12, 211
hormones, non-steroidal, 1, 191; 3, 184
hormones, peptide, 5, 210; 7, 194; 8, 204; 10, 202; 11, 158; 16, 199
hormones, steroid, 1, 213; 2, 208; 3, 207; 4, 199
host modulation, infection, 8, 160; 14, 146; 18, 149
Hsp90 inhibitors, 40, 263
5-HT2C receptor modulator, 37, 21

human dose projections, 43, 311
human gene therapy, 26, 315; 28, 267
human retrovirus regulatory proteins, 26, 171
hybrid antibacterial agents, 43, 281
11 β -hydroxysteroid dehydrogenase type 1 inhibitors, 41, 127
5-hydroxytryptamine, 2, 273; 7, 47; 21, 41
5-hydroxytryptamine –5-HT5A, 5-HT6, and 5-HT7, 43, 25
hypercholesterolemia, 24, 147
hypersensitivity, delayed, 8, 284
hypersensitivity, immediate, 7, 238; 8, 273
hypertension, 28, 69
hypertension, etiology, 9, 50
hypnotics, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39; 8, 29; 10, 30; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22, 16; 31; 17, 11; 18, 11; 19, 11; 22, 11
ICE gene family, 31, 249
IgE, 18, 247
I κ B kinase inhibitors, 43, 155
Immune cell signaling, 38, 275
immune mediated idiosyncratic drug hypersensitivity, 26, 181
immune system, 35, 281
immunity, cellular mediated, 17, 191; 18, 265
immunoassay, enzyme, 18, 285
immunomodulatory proteins, 35, 281
immunophilins, 28, 207
immunostimulants, arthritis, 11, 138; 14, 146
immunosuppressants, 26, 211; 29, 175
immunosuppressive drug action, 28, 207
immunosuppressives, arthritis, 11, 138
immunotherapy, cancer, 9, 151; 23, 151
immunotherapy, infectious diseases, 18, 149; 22, 127
immunotherapy, inflammation, 23, 171
infections, sexually transmitted, 14, 114
infectious disease strategies, 41, 279
inflammation, 22, 245; 31, 279
inflammation, immunomodulatory approaches, 23, 171
inflammation, proteinases in, 28, 187
inflammatory bowel disease, 24, 167, 38, 141
inhibition of bacterial fatty acid biosynthesis, 45, 295
inhibitors, AKT/PKB kinase, 42, 365
inhibitors and modulators, amyloid secretase, 42, 27
inhibitors, anti-apoptotic proteins, 40, 245
inhibitors, cathepsin K, 42, 111
inhibitors, complement, 15, 193
inhibitors, connective tissue, 17, 175
inhibitors, dipeptidyl peptidase 4, 40, 149
inhibitors, enzyme, 13, 249
inhibitors, glutathione S-transferase, 42, 321
inhibitors, HCV, 42, 281
inhibitors, histone deacetylase, 42, 337
inhibitors, influenza neuraminidase, 41, 287
inhibitors, irreversible, 9, 234; 16, 289
inhibitors. MAP kinases, 42, 265

inhibitors, mitotic kinesin, 41, 263
inhibitors, monoamine reuptake, 42, 13
inhibitors, PDEs, 42, 3
inhibitors, platelet aggregation, 6, 60
inhibitors, proteolytic enzyme, 13, 261
inhibitors, renin, 41, 155
inhibitors, renin-angiotensin, 13, 82
inhibitors, reverse transcription, 8, 251
inhibitors, spleen tyrosine kinase (Syk), 42, 379
inhibitors, transition state analogs, 7, 249
inorganic chemistry, medicinal, 8, 294
inosine monophosphate dehydrogenase, 35, 201
inositol triphosphate receptors, 27, 261
insecticides, 9, 300; 17, 311
insomnia treatments, 42, 63
in silico approaches, prediction of human volume of distribution, 42, 469
insulin, mechanism, 18, 193
insulin-like growth factor receptor (IGF-1R) inhibitors, 44, 281
integrins, 31, 191
 β_2 —integrin Antagonist, 36, 181
integrin alpha 4 beta 1 (VLA-4), 34, 179
intellectual property, 36, 331
interferon, 8, 150; 12, 211; 16, 229; 17, 151
interleukin-1, 20, 172; 22, 235; 25, 185; 29, 205, 33, 183
interleukin-2, 19, 191
interoceptive discriminative stimuli, animal model of anxiety, 15, 51
intracellular signaling targets, 37, 115
intramolecular catalysis, 7, 279
ion channel modulators, 37, 237
ion channels, ligand gated, 25, 225
ion channels, voltage-gated, 25, 225
ionophores, monocarboxylic acid, 10, 246
ionotropic GABA receptors, 39, 11
iron chelation therapy, 13, 219
irreversible ligands, 25, 271
ischemia/reperfusion, CNS, 27, 31
ischemic injury, CNS, 25, 31
isotopes, stable, 12, 319; 19, 173
isotopically labeled compounds in drug discovery, 44, 515
JAK3 Inhibitors, 44, 247
JAKs, 31, 269
Janus kinase 2 (JAK2) inhibitors, 45, 211
ketolide antibacterials, 35, 145
Kv7 Modulators, 46, 53
 β -lactam antibiotics, 11, 271; 12, 101; 13, 149; 20, 127, 137; 23, 121; 24, 101
 β -lactamases, 13, 239; 17, 119; 43, 247
LDL cholesterol, 35, 251
learning, 3, 279; 16, 51
leptin, 32, 21
leukocyte elastase inhibitors, 29, 195
leukocyte motility, 17, 181
leukotriene biosynthesis inhibitors, 40, 199

leukotriene modulators, 32, 91
leukotrienes, 17, 291; 19, 241; 24, 71
LHRH, 20, 203; 23, 211
lipid metabolism, 9, 172; 10, 182; 11, 180; 12, 191; 13, 184; 14, 198; 15, 162
lipoproteins, 25, 169
liposomes, 14, 250
lipoxygenase, 16, 213; 17, 203
LXR agonists, 43, 103
lymphocytes, delayed hypersensitivity, 8, 284
macrocyclic immunomodulators, 25, 195
macrolide antibacterials, 35, 145
macrolide antibiotics, 25, 119
macrophage migration inhibitor factor, 33, 243
magnetic resonance, drug binding, 11, 311
malaria, 31, 141; 34, 349, 38, 203
male contraception, 32, 191
managed care, 30, 339
MAP kinase, 31, 289
market introductions, 19, 313; 20, 315; 21, 323; 22, 315; 23, 325; 24, 295; 25, 309; 26, 297; 27, 321; 28, 325; 29, 331; 30, 295; 31, 337; 32, 305; 33, 327
mass spectrometry, 31, 319; 34, 307
mass spectrometry, of peptides, 24, 253
mass spectrometry, tandem, 21, 213; 21, 313
mast cell degranulation, biochemistry, 18, 247
matrix metalloproteinase, 37, 209
matrix metalloproteinase inhibitors, 35, 167
mechanism based, anticancer agents, 25, 129
mechanism, drug allergy, 3, 240
mechanism of action in drug discovery, 46, 301
mechanisms of antibiotic resistance, 7, 217; 13, 239; 17, 119
medicinal chemistry, 28, 343; 30, 329; 33, 385; 34, 267
melanin-concentrating hormone, 40, 119
melanocortin-4 receptor, 38, 31
melatonin, 32, 31
melatonin agonists, 39, 21
membrane function, 10, 317
membrane regulators, 11, 210
membranes, active transport, 11, 222
memory, 3, 279; 12, 30; 16, 51
metabolism, cell, 1, 267; 2, 286
metabolism, drug, 3, 227; 4, 259; 5, 246; 6, 205; 8, 234; 9, 290; 11, 190; 12, 201; 13, 196, 304; 14, 188; 23, 265, 315
metabolism, lipid, 9, 172; 10, 182; 11, 180; 12, 191; 14, 198
metabolism, mineral, 12, 223
metabonomics, 40, 387
metabotropic glutamate receptor, 35, 1, 38, 21
metabotropic glutamate receptor (group III) modulators, 46, 3
metal carbonyls, 8, 322
metalloproteinases, 31, 231; 33, 131
metals, disease, 14, 321
metastasis, 28, 151
methyl lysine, 45, 329

microbial genomics, 37, 95
microbial products screening, 21, 149
microRNAs as therapeutics, 46, 351
microtubule stabilizing agents, 37, 125
microwave-assisted chemistry, 37, 247
migraine, 22, 41; 32, 1
mineralocorticoid receptor antagonists, 46, 89
mitogenic factors, 21, 237
mitotic kinesin inhibitors, 39, 135
modified serum lipoproteins, 25, 169
modulators of transient receptor potential ion channels, 45, 37
molecular diversity, 26, 259, 271; 28, 315; 34, 287
molecular libraries screening center network, 42, 401
molecular modeling, 22, 269; 23, 285
monoclonal antibodies, 16, 243; 27, 179; 29, 317
monoclonal antibody cancer therapies, 28, 237
monooxygenases, cytochrome P-450, 9, 290
mTOR inhibitors, 43, 189
multi-factorial diseases, basis of, 41, 337
multivalent ligand design, 35, 321
muscarinic agonists/antagonists, 23, 81; 24, 31; 29, 23
muscle relaxants, 1, 30; 2, 24; 3, 28; 4, 28; 8, 37
muscular disorders, 12, 260
mutagenicity, mutagens, 12, 234
mutagenesis, SAR of proteins, 18, 237
myocardial ischemia, acute, 25, 71
narcotic antagonists, 7, 31; 8, 20; 9, 11; 10, 12; 11, 23; 13, 41
natriuretic agents, 19, 253
natural products, 6, 274; 15, 255; 17, 301; 26, 259; 32, 285
natural killer cells, 18, 265
neoplasia, 8, 160; 10, 142
neuritic plaque in Alzheimer's disease, 45, 315
neurodegeneration, 30, 31
neurodegenerative disease, 28, 11
neurokinin antagonists, 26, 43; 31, 111; 32, 51; 33, 71; 34, 51
neurological disorders, 31, 11
neuronal calcium channels, 26, 33
neuronal cell death, 29, 13
neuropathic pain, 38, 1
neuropeptides, 21, 51; 22, 51
neuropeptide Y, 31, 1; 32, 21; 34, 31
neuropeptide Y receptor modulators, 38, 61
neuropeptide receptor antagonists, 38, 11
neuropharmacokinetic parameters in CNS drug discovery, 45, 55
neuroprotection, 29, 13
neuroprotective agents, 41, 39
neurotensin, 17, 31
neurotransmitters, 3, 264; 4, 270; 12, 249; 14, 42; 19, 303
neutrophilic factors, 25, 245; 28, 11
neutrophil chemotaxis, 24, 233
niacin receptor GPR109A agonists, 45, 73
nicotinic acetylcholine receptor, 22, 281; 35, 41

nicotinic acetylcholine receptor modulators, 40, 3
NIH in preclinical drug development, 45, 361
nitric oxide synthase, 29, 83; 31, 221; 44, 27
NMR, 27, 271
NMR in biological systems, 20, 267
NMR imaging, 20, 277; 24, 265
NMR methods, 31, 299
NMR, protein structure determination, 23, 275
non-enzymatic glycosylation, 14, 261
non-HIV antiviral agents, 36, 119, 38, 213
non-nutritive, sweeteners, 17, 323
non-peptide agonists, 32, 277
non-peptidic d-opioid agonists, 37, 159
non-steroidal antiinflammatories, 1, 224; 2, 217; 3, 215; 4, 207; 5, 225; 6, 182; 7, 208; 8, 214; 9, 193; 10, 172; 13, 167; 16, 189
non-steroidal glucocorticoid receptor agonists, 43, 141
novel analgesics, 35, 21
NSAIDs, 37, 197
nuclear hormone receptor/steroid receptor coactivator inhibitors, 44, 443
nuclear orphan receptors, 32, 251
nucleic acid-drug interactions, 13, 316
nucleic acid, sequencing, 16, 299
nucleic acid, synthesis, 16, 299
nucleoside conformation, 5, 272
nucleosides, 1, 299; 2, 304; 3, 297; 5, 333; 39, 241
nucleotide metabolism, 21, 247
nucleotides, 1, 299; 2, 304; 3, 297; 5, 333; 39, 241
nucleotides, cyclic, 9, 203; 10, 192; 15, 182
obesity, 1, 51; 2, 44; 3, 47; 5, 40; 8, 42; 11, 200; 15, 172; 19, 157; 23, 191; 31, 201; 32, 21
obesity therapeutics, 38, 239
obesity treatment, 37, 1
oligomerisation, 35, 271
oligonucleotides, inhibitors, 23, 295
oncogenes, 18, 225; 21, 159, 237
opioid receptor, 11, 33; 12, 20; 13, 41; 14, 31; 15, 32; 16, 41; 17, 21; 18, 51; 20, 21; 21, 21
opioid receptor antagonists, 45, 143
opioids, 12, 20; 16, 41; 17, 21; 18, 51; 20, 21; 21, 21
opportunistic infections, 29, 155
oral pharmacokinetics, 35, 299
organocopper reagents, 10, 327
osteoarthritis, 22, 179
osteoporosis, 22, 169; 26, 201; 29, 275; 31, 211
oxazolidinone antibacterials, 35, 135
oxytocin antagonists and agonists, 41, 409
P38a MAP kinase, 37, 177
P-glycoprotein, multidrug transporter, 25, 253
pain therapeutics, 46, 19
parallel synthesis, 34, 267
parasite biochemistry, 16, 269
parasitic infection, 36, 99
patents in drug discovery, 45, 449
patents in medicinal chemistry, 22, 331

pathophysiology, plasma membrane, 10, 213
PDE IV inhibitors, 31, 71
PDE7 inhibitors, 40, 227
penicillin binding proteins, 18, 119
peptic ulcer, 1, 99; 2, 91; 4, 56; 6, 68; 8, 93; 10, 90; 12, 91; 16, 83; 17, 89; 18, 89; 19, 81; 20, 93; 22, 191; 25, 159
peptide-1, 34, 189
peptide conformation, 13, 227; 23, 285
peptide hormones, 5, 210; 7, 194; 8, 204; 10, 202; 11, 158, 19, 303
peptide hypothalamus, 7, 194; 8, 204; 10, 202; 16, 199
peptide libraries, 26, 271
peptide receptors, 25, 281; 32, 277
peptide, SAR, 5, 266
peptide stability, 28, 285
peptide synthesis, 5, 307; 7, 289; 16, 309
peptide synthetic, 1, 289; 2, 296
peptide thyrotropin, 17, 31
peptidomimetics, 24, 243
periodontal disease, 10, 228
peptidyl prolyl isomerase inhibitors, 46, 337
peroxisome proliferator — activated receptors, 38, 71
PET, 24, 277
PET imaging agents, 40, 49
PET ligands, 36, 267
pharmaceutics, 1, 331; 2, 340; 3, 337; 4, 302; 5, 313; 6, 254, 264; 7, 259; 8, 332
pharmaceutical innovation, 40, 431
pharmaceutical productivity, 38, 383
pharmaceutical proteins, 34, 237
pharmacogenetics, 35, 261; 40, 417
pharmacogenomics, 34, 339
pharmacokinetics, 3, 227, 337; 4, 259, 302; 5, 246, 313; 6, 205; 8, 234; 9, 290; 11, 190; 12, 201; 13, 196, 304; 14, 188, 309; 16, 319; 17, 333
pharmacophore identification, 15, 267
pharmacophoric pattern searching, 14, 299
phosphatidyl-inositol-3-kinases (PI3Ks) inhibitors, 44, 339
phosphodiesterase, 31, 61
phosphodiesterase 4 inhibitors, 29, 185; 33, 91; 36, 41
phosphodiesterase 5 inhibitors, 37, 53
phospholipases, 19, 213; 22, 223; 24, 157
phospholipidosis, 46, 419
physicochemical parameters, drug design, 3, 348; 4, 314; 5, 285
physicochemical properties and ligand efficiency and drug safety risks, 45, 381
pituitary hormones, 7, 194; 8, 204; 10, 202
plants, 34, 237
plasma membrane pathophysiology, 10, 213
plasma protein binding, 31, 327
plasma protein binding, free drug principle, 42, 489
plasminogen activator, 18, 257; 20, 107; 23, 111; 34, 121
plasmon resonance, 33, 301
platelet activating factor (PAF), 17, 243; 20, 193; 24, 81
platelet aggregation, 6, 60
pluripotent stem cells as human disease models, 46, 369

poly(ADP-ribose)polymerase (PARP) inhibitors, 45, 229
polyether antibiotics, 10, 246
polyamine metabolism, 17, 253
polyamine spider toxins, 24, 287
polymeric reagents, 11, 281
positron emission tomography, 24, 277; 25, 261; 44, 501
potassium channel activators, 26, 73
potassium channel antagonists, 27, 89
potassium channel blockers, 32, 181
potassium channel openers, 24, 91, 30, 81
potassium channel modulators, 36, 11
potassium channels, 37, 237
pregnane X receptor and CYP3A4 enzyme, 43, 405
privileged structures, 35, 289
prodrugs, 10, 306; 22, 303
prodrug discovery, oral, 41, 395
profiling of compound libraries, 36, 277
programmed cell death, 30, 239
prolactin secretion, 15, 202
prostacyclin, 14, 178
prostaglandins, 3, 290; 5, 170; 6, 137; 7, 157; 8, 172; 9, 162; 11, 80; 43, 293
prostanoid receptors, 33, 223
prostatic disease, 24, 197
protease inhibitors for COPD, 43, 171
proteases, 28, 151
proteasome, 31, 279
protein C, 29, 103
protein growth factors, 17, 219
proteinases, arthritis, 14, 219
protein kinases, 18, 213; 29, 255
protein kinase C, 20, 227; 23, 243
protein phosphatases, 29, 255
protein-protein interactions, 38, 295; 44, 51
protein structure determination, NMR, 23, 275
protein structure modeling, 39, 203
protein structure prediction, 36, 211
protein structure project, 31, 357
protein tyrosine kinases, 27, 169
protein tyrosine phosphatase, 35, 231
proteomics, 36, 227
psoriasis, 12, 162; 32, 201
psychiatric disorders, 11, 42
psychoses, biological factors, 10, 39
psychotomimetic agents, 9, 27
pulmonary agents, 1, 92; 2, 83; 3, 84; 4, 67; 5, 55; 7, 89; 9, 85; 10, 80; 11, 51; 12, 70; 13, 51; 14, 51; 15, 59; 17, 51; 18, 61; 20, 71; 21, 73; 22, 73; 23, 69; 24, 61; 25, 61; 26, 113; 27, 109
pulmonary disease, 34, 111
pulmonary hypertension, 37, 41
pulmonary inflammation, 31, 71
pulmonary inhalation technology, 41, 383
purine and pyrimide nucleotide (P2) receptors, 37, 75
purine-binding enzymes, 38, 193

purinoceptors, 31, 21
QT interval prolongation, 39, 255
quantitative SAR, 6, 245; 8, 313; 11, 301; 13, 292; 17, 281
quinolone antibacterials, 21, 139; 22, 117; 23, 133
radioimmunoassays, 10, 284
radioisotope labeled drugs, 7, 296
radioimaging agents, 18, 293
radioligand binding, 19, 283
radiosensitizers, 26, 151
ras farnesyltransferase, 31, 171
ras GTPase, 26, 249
ras oncogene, 29, 165
receptor binding, 12, 249
receptor mapping, 14, 299; 15, 267; 23, 285
receptor modeling, 26, 281
receptor modulators, nuclear hormone, 41, 99
receptor, concept and function, 21, 211
receptors, acetylcholine, 30, 41
receptors, adaptive changes, 19, 241
receptors, adenosine, 28, 295; 33, 111
receptors, adrenergic, 15, 217
receptors, b-adrenergic blockers, 14, 81
receptors, benzodiazepine, 16, 21
receptors, cell surface, 12, 211
receptors, drug, 1, 236; 2, 227; 8, 262
receptors, G-protein coupled, 23, 221, 27, 291
receptors, G-protein coupled CNS, 28, 29
receptors, histamine, 14, 91
receptors, muscarinic, 24, 31
receptors, neuropeptide, 28, 59
receptors, neuronal BZD, 28, 19
receptors, neurotransmitters, 3, 264; 12, 249
receptors, neuroleptic, 12, 249
receptors, opioid, 11, 33; 12, 20; 13, 41; 14, 31; 15, 32; 16, 41; 17, 21
receptors, peptide, 25, 281
receptors, serotonin, 23, 49
receptors, sigma, 28, 1
recombinant DNA, 17, 229; 18, 307; 19, 223
recombinant therapeutic proteins, 24, 213
renal blood flow, 16, 103
renin, 13, 82; 20, 257
reperfusion injury, 22, 253
reproduction, 1, 205; 2, 199; 3, 200; 4, 189
resistant organisms, 34, 169
respiratory syncytial virus, 43, 229
respiratory tract infections, 38, 183
retinoids, 30, 119
reverse transcription, 8, 251
RGD-containing proteins, 28, 227
rheumatoid arthritis, 11, 138; 14, 219; 18, 171; 21, 201; 23, 171, 181
rho-kinase inhibitors, 43, 87
ribozymes, 30, 285

RNAi, 38, 261
safety testing of drug metabolites, 44, 459
SAR, quantitative, 6, 245; 8, 313; 11, 301; 13, 292; 17, 291
same brain, new decade, 36, 1
schizophrenia, treatment of, 41, 3
secretase inhibitors, 35, 31; 38, 41
sedative-hypnotics, 7, 39; 8, 29; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22; 16, 31; 17, 11; 18, 11; 19, 11; 22, 11
sedatives, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39; 8, 29; 10, 30; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22; 16, 31; 17, 11; 18, 11; 20, 1; 21, 11
semicarbazide sensitive amine oxidase and VAP-1, 42, 229
sequence-defined oligonucleotides, 26, 287
serine protease inhibitors in coagulation, 44, 189
serine proteases, 32, 71
SERMs, 36, 149
serotonergics, central, 25, 41; 27, 21
serotonergics, selective, 40, 17
serotonin, 2, 273; 7, 47; 26, 103; 30, 1; 33, 21
serotonin receptor, 35, 11
serum lipoproteins, regulation, 13, 184
sexually-transmitted infections, 14, 114
SGLT2 inhibitors, 46, 103
SH2 domains, 30, 227
SH3 domains, 30, 227
silicon, in biology and medicine, 10, 265
sickle cell anemia, 20, 247
signal transduction pathways, 33, 233
skeletal muscle relaxants, 8, 37
sleep, 27, 11; 34, 41
slow-reacting substances, 15, 69; 16, 213; 17, 203, 291
Smac mimetics as apoptosis inhibitors, 46, 211
SNPs, 38, 249
sodium/calcium exchange, 20, 215
sodium channel blockers, 41, 59; 43, 43
sodium channels, 33, 51
solid-phase synthesis, 31, 309
solid state organic chemistry, 20, 287
solute active transport, 11, 222
somatostatin, 14, 209; 18, 199; 34, 209
sphingomyelin signaling path, 43, 203
sphingosine 1 receptor modulators, 42, 245
spider toxins, 24, 287
SRS, 15, 69; 16, 213; 17, 203, 291
Statins, 37, 197; 39, 187
Statins, pleiotropic effects of, 39, 187
STATs, 31, 269
stereochemistry, 25, 323
steroid hormones, 1, 213; 2, 208; 3, 207; 4, 199
stroidogenesis, adrenal, 2, 263
steroids, 2, 312; 3, 307; 4, 281; 5, 192, 296; 6, 162; 7, 182; 8, 194; 11, 192
stimulants, 1, 12; 2, 11; 3, 14; 4, 13; 5, 13; 6, 15; 7, 18; 8, 11
stroke, pharmacological approaches, 21, 108

stromelysin, biochemistry, 25, 177
structural genomics, 40, 349
structure-based drug design, 27, 271; 30, 265; 34, 297
substance P, 17, 271; 18, 31
substituent constants, 2, 347
suicide enzyme inhibitors, 16, 289
superoxide dismutases, 10, 257
superoxide radical, 10, 257
sweeteners, non-nutritive, 17, 323
synthesis, asymmetric, 13, 282
synthesis, computer-assisted, 12, 288; 16, 281; 21, 203
synthesis, enzymic, 23, 305
systems biology and kinase signaling, 42, 393
T-cells, 27, 189; 30, 199; 34, 219
tachykinins, 28, 99
target identification, 41, 331
taxol, 28, 305
technology, providers and integrators, 33, 365
tetracyclines, 37, 105
Th17 and Treg signaling pathways, 46, 155
thalidomide, 30, 319
therapeutic antibodies, s,36, 237
thrombin, 30, 71, 31, 51; 34, 81
thrombolytic agents, 29, 93
thrombosis, 5, 237; 26, 93; 33, 81
thromboxane receptor antagonists, 25, 99
thromboxane synthase inhibitors, 25, 99
thromboxane synthetase, 22, 95
thromboxanes, 14, 178
thyrotropin releasing hormone, 17, 31
tissue factor pathway, 37, 85
TNF- α , 32, 241
TNF- α converting enzyme, 38, 153
toll-like receptor (TLR) signaling, 45, 191
topical microbicides, 40, 277
topoisomerase, 21, 247; 44, 379
toxicity, mathematical models, 18, 303
toxicity reversal, 15, 233
toxicity, structure activity relationships for, 41, 353
toxicogenomics, 44, 555
toxicology, comparative, 11, 242; 33, 283
toxins, bacterial, 12, 211
transcription factor NF- κ B, 29, 235
transcription, reverse, 8, 251
transcriptional profiling, 42, 417
transgenic animals, 24, 207
transgenic technology, 29, 265
transient receptor potential modulators, 42, 81
translational control, 29, 245
translation initiation inhibition for cancer therapy, 46, 189
transporters, drug, 39, 219
traumatic injury, CNS, 25, 31

triglyceride synthesis pathway, 45, 109
trophic factors, CNS, 27, 41
TRPV1 vanilloid receptor, 40, 185
tumor classification, 37, 225
tumor necrosis factor, 22, 235
type 2 diabetes, 35, 211; 40, 167
tyrosine kinase, 30, 247; 31, 151
urinary incontinence, 38, 51
urokinase-type plasminogen activator, 34, 121
urotensin-II receptor modulators, 38, 99
vanilloid receptor, 40, 185
vascular cell adhesion molecule-1, 41, 197
vascular proliferative diseases, 30, 61
vasoactive peptides, 25, 89; 26, 83; 27, 79
vasoconstrictors, 4, 77
vasodilators, 4, 77; 12, 49
vasopressin antagonists, 23, 91
vasopressin receptor ligands, 44, 129
vasopressin receptor modulators, 36, 159
veterinary drugs, 16, 161
viruses, 14, 238
vitamin D, 10, 295; 15, 288; 17, 261; 19, 179
voltage-gated calcium channel antagonists, 45, 5
waking functions, 10, 21
water, structures, 5, 256
wound healing, 24, 223
xenobiotics, cyclic nucleotide metabolism, 15, 182
xenobiotic metabolism, 23, 315
X-ray crystallography, 21, 293; 27, 271